168 related articles for article (PubMed ID: 67884)
1. Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine.
Voytek P; Beisler JA; Abbasi MM; Wolpert-DeFilippes MK
Cancer Res; 1977 Jul; 37(7 Pt 1):1956-61. PubMed ID: 67884
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and cytotoxicity of 5-azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin.
Plagemann PG; Behrens M; Abraham D
Cancer Res; 1978 Aug; 38(8):2458-66. PubMed ID: 78761
[TBL] [Abstract][Full Text] [Related]
3. Studies on the cytostatic action, phosphorylation and deamination of 5-azacytidine and 5,6-dihydro-5-azacytidine in HeLa cells.
Futterman B; Derr J; Beisler JA; Abbasi MM; Voytek P
Biochem Pharmacol; 1978 Mar; 27(6):907-9. PubMed ID: 77670
[No Abstract] [Full Text] [Related]
4. Biological characterization of a prolonged antileukemic effect of 5-azacytidine.
Presant CA; Valeriote F; Vietti TJ
Cancer Res; 1977 Feb; 37(2):376-81. PubMed ID: 64294
[TBL] [Abstract][Full Text] [Related]
5. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
Neil GL; Moxley TE; Kuentzel SL; Manak RC; Hanka LJ
Cancer Chemother Rep; 1975; 59(3):459-65. PubMed ID: 54211
[TBL] [Abstract][Full Text] [Related]
6. Identification of cytidine deaminase as inhibitor of granulocyte-macrophage colony formation.
Bøyum A; Løvhaug D; Seeberg E; Nordlie EM
Exp Hematol; 1994 Feb; 22(2):208-14. PubMed ID: 7507861
[TBL] [Abstract][Full Text] [Related]
7. Alterations in differentiation and pyrimidine pathway enzymes in 5-azacytidine resistant variants of a myoblast line.
Ng SK; Rogers J; Sanwal BD
J Cell Physiol; 1977 Feb; 90(2):361-47. PubMed ID: 65357
[TBL] [Abstract][Full Text] [Related]
8. The effect of 5-azacytidine and dihydro-5-azacytidine on nuclear ribosomal RNA and poly(A) RNA synthesis in L1210 cells in vitro.
Glazer RI; Peale AL; Beisler JA; Abbasi MM
Mol Pharmacol; 1980 Jan; 17(1):111-7. PubMed ID: 6155602
[No Abstract] [Full Text] [Related]
9. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
10. Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis.
Grant S; Bhalla K; Gleyzer M
Cancer Res; 1984 Dec; 44(12 Pt 1):5505-10. PubMed ID: 6208998
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
12. Dihydro-5-azacytidine hydrochloride, a biologically active and chemically stable analog of 5-azacytidine.
Beisler JA; Abbasi MM; Driscoll JS
Cancer Treat Rep; 1976 Nov; 60(11):1671-4. PubMed ID: 66095
[No Abstract] [Full Text] [Related]
13. In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine.
Momparler RL; Goodman J
Cancer Res; 1977 Jun; 37(6):1636-9. PubMed ID: 66984
[TBL] [Abstract][Full Text] [Related]
14. Cytidine 5'-triphosphate synthetase as a target for inhibition by the antitumor agent 3-deazauridine.
McPartland RP; Wang MC; Bloch A; Weinfeld H
Cancer Res; 1974 Nov; 34(11):3107-11. PubMed ID: 4472653
[No Abstract] [Full Text] [Related]
15. Incorporation of a potent antileukemic agent, 5-aza-2'-deoxycytidine, into DNA of cells from leukemic mice.
Veselý J; Cihák A
Cancer Res; 1977 Oct; 37(10):3684-9. PubMed ID: 71199
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of the reduction in viability of cultured L1210 leukemia cells exposed to 5-azacytidine (NSC-102816).
Lloyd HH; Dulmadge EA; Wilkoff LJ
Cancer Chemother Rep; 1972 Oct; 56(5):585-91. PubMed ID: 4119906
[No Abstract] [Full Text] [Related]
18. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro.
Furner RL; Mellett LB; Herren TC
J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of 5-aza-2'-deoxycytidine phosphorylation in mouse spleen and L1210 leukemic cell extracts.
Veselý J; Cihák A
Neoplasma; 1980; 27(2):121-7. PubMed ID: 6156420
[TBL] [Abstract][Full Text] [Related]
20. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
